Skip to content

SER-287 Might Be A New Microbiome Therapeutic For Ulcerative Colitis

Happy 4th of July to All the UC’ers celebrating this day. It is nice to be back in the United States for a 4th of July after many years away. Nice to see the old red white and blue flags flying, and nice to know there are some pretty cool advances taking place in several biotech companies for ulcerative colitis.

Seres Therapeutics

So, check this out, Seres Therapeutics is moving along, well into Phase 2 of their drug development process for something they are calling SER-287. The product overview states this:

SER-287 is an investigational, oral, biologically-derived microbiome therapeutic for the treatment of ulcerative colitis (UC). SER-287 is a consortium of multiple bacterial spores manufactured by fractionating and purifying targeted bacteria from stool of healthy human donors. SER-287 has been granted Fast Track designation and Orphan Drug designation by the FDA. A completed SER-287 Phase 1b clinical study demonstrated a statistically significant difference in the clinical remission rate between patients with active mild-to-moderate ulcerative colitis treated with vancomycin followed by daily SER-287 for 8 weeks compared to the placebo group, and a favorable safety profile.

https://www.serestherapeutics.com/our-programs/

I’m no biology expert, but this sounds like the idea of going through stool samples and taking out bacteria and reproducing them to make a pill form poop tablet is really coming together. Impressive, and for the gut bacteria enthusiasts, pretty interesting eh..?:)

If you are interested in learning more about the clinical trials and programs of this company, you can check out some more details here: https://www.serestherapeutics.com/patients-and-physicians/